{"schema_version":"secwatch.filing_event.v1","accession":"0000896262-24-000018","form_type":"8-K","ticker":null,"cik":"0000896262","company_name":"AMEDISYS INC","filed_at":"2024-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.366287+00:00","generated_at":"2026-06-03T10:56:28.769050+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Amedisys Q1 revenue up to $571.4M; adjusted EPS $1.03 vs $1.00 YoY","bullets":["Net service revenue $571.4M, up $15.0M YoY; prior year included $15M from divested personal care.","GAAP net income $14.4M ($0.44 diluted EPS) vs $25.2M ($0.77) in 2023; includes $20.7M merger expenses.","Adjusted EBITDA $59.9M vs $57.8M; adjusted net income $33.9M ($1.03 diluted EPS) vs $32.7M ($1.00)."],"urls":{"canonical":"https://secwatch.observer/filing/0000896262-24-000018","json":"https://secwatch.observer/filing/0000896262-24-000018.json","markdown":"https://secwatch.observer/filing/0000896262-24-000018.md","text":"https://secwatch.observer/filing/0000896262-24-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896262/000089626224000018/0000896262-24-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896262/000089626224000018/amed-20240424.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T10:56:28.769050+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"85d46421072e6ae79f0c752de5b4bcca95a380ed","claim":"AMEDISYS INC reported three-month period ended March 31, 2024 results: revenue Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023., net income Net income attributable to Amedisys, Inc. of $14.4 million, EPS Net income attributable to Amedisys, Inc. per diluted share of $0.44 compared to $0.77 in 2023..","evidence_excerpt":"On April 24, 2024, Amedisys, Inc. (\"we,\" \"us,\" \"our,\" or \"the Company\") issued a press release (the “Press Release”) announcing its financial results for the three-month period ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/896262/000089626224000018/0000896262-24-000018-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three-month period ended March 31, 2024"},{"label":"Revenue","value":"Net service revenue increased $15.0 million to $571.4 million compared to $556.4 million in 2023."},{"label":"Net income","value":"Net income attributable to Amedisys, Inc. of $14.4 million"},{"label":"EPS","value":"Net income attributable to Amedisys, Inc. per diluted share of $0.44 compared to $0.77 in 2023."},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}